Want to see SNN full AI Analyst Report?
SNN Stock Chart & Stats
$30.57
$0.55(1.80%)
At close: 4:00 PM EDT
$30.57
$0.55(1.80%)
Day’s Range― - ―
52-Week Range$28.56 - $38.79
Previous Close$31.12
Volume1.69M
Average Volume (3M)482.36K
Market Cap
$12.22B
Enterprise Value$15.98K
Total Cash (Recent Filing)$754.00M
Total Debt (Recent Filing)$3.79B
Price to Earnings (P/E)19.2
Beta0.51
Next Earnings
Feb 23, 2027EPS Estimate
1.21Next Dividend Ex-DateN/A
Dividend Yield2.57%
Share Statistics
EPS (TTM)1.50
Shares Outstanding418,708,560
10 Day Avg. Volume593,629
30 Day Avg. Volume482,356
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)2.69
Price to Sales (P/S)2.31
P/FCF Ratio16.69
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$31.89Price Target Upside4.30% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)2.21
Revenue Forecast (FY)$6.50B
Bulls Say, Bears Say
Bulls Say
Margin And Revenue ImprovementThe expanding revenue base and recovery in operating profitability indicate stronger underlying economics. Stable gross margins near 68–70% provide a durable buffer for reinvestment and resilience when procedure volumes or product mix fluctuate.
Efficiency And Cash GenerationSavings delivered ahead of plan can support profit growth even when revenue momentum is modest. Maintaining free-cash-flow guidance alongside higher efficiency targets suggests cost discipline is becoming a lasting earnings and funding advantage.
Product And Platform GrowthStrong growth in sports medicine platforms, recurring procedure-related consumables and continued launches diversify the portfolio beyond weaker orthopaedic areas. FDA approval and new systems can expand surgeon adoption and support multi-year share gains.
Bears Say
Slowing Top-Line GrowthThe lower revenue outlook signals that portfolio gaps and procedure-market challenges are not merely isolated quarterly issues. Persistently slower growth could limit operating leverage, reduce strategic flexibility and make profit targets increasingly dependent on cost savings.
Wound-Care Reimbursement PressureReimbursement changes and billing friction can structurally reduce demand or pricing in advanced wound care. A prolonged reset in skin substitutes and bioactives would weigh on portfolio growth and require sustained investment or efficiency offsets.
Moderate Leverage And Weak ConversionModerate leverage is manageable, but limited deleveraging reduces financial flexibility if margins weaken or growth slows. Free cash flow below accounting profit also indicates working-capital or investment demands may constrain discretionary cash available for reinvestment.
SNN FAQ
What was Smith & Nephew Snats’s price range in the past 12 months?
Smith & Nephew Snats lowest stock price was $28.55 and its highest was $38.79 in the past 12 months.
What is Smith & Nephew Snats’s market cap?
Smith & Nephew Snats’s market cap is $12.22B.
When is Smith & Nephew Snats’s upcoming earnings report date?
Smith & Nephew Snats’s upcoming earnings report date is Feb 23, 2027 which is in 183 days.
How were Smith & Nephew Snats’s earnings last quarter?
Smith & Nephew Snats released its earnings results on Aug 04, 2026. The company reported $0.946 earnings per share for the quarter, beating the consensus estimate of $0.939 by $0.007.
Is Smith & Nephew Snats overvalued?
According to Wall Street analysts Smith & Nephew Snats’s price is currently Undervalued.
Does Smith & Nephew Snats pay dividends?
Smith & Nephew Snats pays a Semiannually dividend of $0.312 which represents an annual dividend yield of 2.57%. See more information on Smith & Nephew Snats dividends here
What is Smith & Nephew Snats’s EPS estimate?
Smith & Nephew Snats’s EPS estimate is 1.21.
How many shares outstanding does Smith & Nephew Snats have?
Smith & Nephew Snats has 418,708,560 shares outstanding.
What happened to Smith & Nephew Snats’s price movement after its last earnings report?
Smith & Nephew Snats reported an EPS of $0.946 in its last earnings report, beating expectations of $0.939. Following the earnings report the stock price went down -5.319%.
Which hedge fund is a major shareholder of Smith & Nephew Snats?
Currently, no hedge funds are holding shares in SNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Smith & Nephew Snats Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$31.89 (4.30% Upside)
$31.89 (4.30% Upside)
Blogger Sentiment
Neutral
SNN Sentiment 50%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.53%
12-Months-Change
Fundamentals
Return on Equity
2.57%
Trailing 12-Months
Asset Growth
3.66%
Trailing 12-Months
Company Description
Smith & Nephew Snats
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
SNN Company Deck
SNN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call painted a mixed picture: revenue growth came in below expectations, driven by weakness in U.S. Orthopaedics and reimbursement-related pressure in skin substitutes and bioactives. However, the company delivered strong profit and margin expansion, materially outperformed on efficiency savings (raising 2026 savings guidance), maintained trading profit, free cash flow and ROIC guidance, and highlighted multiple product and geographic growth drivers (notably in Sports Medicine & ENT, emerging markets, and a range of innovation milestones). Near‑term execution and reimbursement challenges create risk to topline momentum, but operational improvements and cost discipline have preserved earnings and cash targets.View all SNN earnings summariesSNN Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$31.89
▲(4.30% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Boston Scientific
―
Edwards Lifesciences
―
Medtronic
―
Stryker
―
Zimmer Biomet Holdings
―
Ownership Overview
―
Insiders
0.31% Mutual Funds
2.83% Other Institutional Investors
96.59% Public Companies and
Individual Investors











